On 14 July 2016, orphan designation (EU/3/16/1698) was granted by the European Commission to Immungenetics AG, Germany, for dimethyl fumarate for the treatment of bullous pemphigoid.
The sponsorship was transferred to Novalis Investments S.L. in February 2019.
|Disease / condition||
Treatment of bullous pemphigoid
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.